CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-28 | Lynx1 Capital Management LP 10% owner | Purchase | +165,667 | $8.40 | $1.4M | 8,963,500 |
| 2025-10-17 | Lynx1 Capital Management LP 10% owner | Purchase | +32,217 | $7.84 | $253K | 8,797,833 |
| 2025-10-16 | Lynx1 Capital Management LP 10% owner | Purchase | +150,000 | $8.86 | $1.3M | 8,765,616 |
| 2025-10-15 | Lynx1 Capital Management LP 10% owner | Purchase | +51,500 | $7.94 | $409K | 8,615,616 |
| 2025-10-14 | Lynx1 Capital Management LP 10% owner | Purchase | +15,032 | $7.59 | $114K | 8,564,116 |
| 2025-10-10 | Lynx1 Capital Management LP 10% owner | Purchase | +277,298 | $7.36 | $2.0M | 8,549,084 |
| 2025-10-09 | Lynx1 Capital Management LP 10% owner | Purchase | +626,043 | $6.70 | $4.2M | 8,271,786 |
| 2025-10-08 | Lynx1 Capital Management LP 10% owner | Purchase | +556,300 | $6.46 | $3.6M | 7,645,743 |
| 2022-06-06 | AHMED NADIM President and CEO | Purchase | +8,090 | $12.40 | $100K | 8,090 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +405,641 | $11.00 | $4.5M | 4,058,854 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +301,009 | $11.00 | $3.3M | 2,992,808 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +44,746 | $11.00 | $492K | 364,161 |
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +53,598 | $9.14 | $490K | 3,653,213 |
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +38,558 | $9.14 | $352K | 2,691,799 |
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +17,744 | $9.14 | $162K | 319,415 |
| 2022-05-12 | BVF PARTNERS L P/IL 10% owner | Purchase | +542,999 | $9.06 | $4.9M | 3,599,615 |
| 2022-05-12 | BVF PARTNERS L P/IL 10% owner | Purchase | +457,001 | $9.06 | $4.1M | 2,653,241 |
| 2022-04-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +266,598 | $10.75 | $2.9M | 3,056,616 |
| 2022-04-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +9,402 | $10.75 | $101K | 2,196,240 |
| 2021-01-12 | UBS Oncology Impact Fund L.P. 10% owner | Purchase | +300,000 | $21.00 | $6.3M | 7,913,887 |
Page 1 of 2 · 25 trades